 Judith Shlay
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sexually Transmitted Diseases | 11 | 2020 | 161 | 2.380 |
Why?
| | Text Messaging | 7 | 2022 | 157 | 2.300 |
Why?
| | School Health Services | 7 | 2015 | 238 | 2.180 |
Why?
| | Sexual Health | 6 | 2022 | 59 | 2.170 |
Why?
| | Immunization Programs | 6 | 2015 | 213 | 2.000 |
Why?
| | Pregnancy in Adolescence | 4 | 2017 | 83 | 1.520 |
Why?
| | Opioid-Related Disorders | 3 | 2022 | 515 | 1.200 |
Why?
| | Safety-net Providers | 2 | 2020 | 119 | 1.170 |
Why?
| | Sexual Behavior | 10 | 2022 | 485 | 1.030 |
Why?
| | Condoms | 5 | 2016 | 103 | 1.020 |
Why?
| | Influenza Vaccines | 4 | 2015 | 539 | 1.010 |
Why?
| | Reimbursement Mechanisms | 3 | 2015 | 85 | 0.940 |
Why?
| | Ambulatory Care Facilities | 5 | 2013 | 232 | 0.830 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2014 | 99 | 0.820 |
Why?
| | Pregnancy, Unwanted | 3 | 2009 | 14 | 0.740 |
Why?
| | Colorado | 15 | 2020 | 4565 | 0.720 |
Why?
| | Analgesics, Opioid | 4 | 2022 | 1000 | 0.710 |
Why?
| | Body Composition | 7 | 2010 | 684 | 0.690 |
Why?
| | Attitude to Health | 2 | 2014 | 439 | 0.680 |
Why?
| | Family Planning Services | 2 | 2013 | 92 | 0.680 |
Why?
| | Contraception Behavior | 2 | 2016 | 102 | 0.660 |
Why?
| | Contraception | 5 | 2022 | 161 | 0.620 |
Why?
| | Papillomavirus Infections | 6 | 2013 | 325 | 0.620 |
Why?
| | HIV Infections | 12 | 2013 | 2836 | 0.580 |
Why?
| | Patient Participation | 2 | 2019 | 420 | 0.570 |
Why?
| | Influenza, Human | 2 | 2014 | 622 | 0.560 |
Why?
| | Anti-HIV Agents | 4 | 2009 | 778 | 0.550 |
Why?
| | Parental Consent | 2 | 2014 | 25 | 0.550 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2008 | 84 | 0.540 |
Why?
| | Opiate Substitution Treatment | 1 | 2019 | 155 | 0.540 |
Why?
| | Sex Education | 1 | 2016 | 30 | 0.510 |
Why?
| | Adolescent | 25 | 2022 | 21513 | 0.490 |
Why?
| | Papanicolaou Test | 4 | 2013 | 43 | 0.490 |
Why?
| | Vaginal Smears | 4 | 2013 | 57 | 0.490 |
Why?
| | Parents | 2 | 2014 | 1347 | 0.480 |
Why?
| | Adolescent Health Services | 1 | 2015 | 71 | 0.450 |
Why?
| | Financing, Government | 1 | 2014 | 47 | 0.440 |
Why?
| | Minority Health | 1 | 2014 | 20 | 0.440 |
Why?
| | Social Values | 1 | 2014 | 36 | 0.430 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2014 | 103 | 0.420 |
Why?
| | Female | 45 | 2022 | 73304 | 0.390 |
Why?
| | Delivery of Health Care | 3 | 2022 | 951 | 0.390 |
Why?
| | Health Care Costs | 2 | 2014 | 398 | 0.390 |
Why?
| | Pregnancy | 14 | 2022 | 6763 | 0.370 |
Why?
| | Geographic Information Systems | 1 | 2011 | 45 | 0.360 |
Why?
| | Tumor Virus Infections | 1 | 2011 | 49 | 0.350 |
Why?
| | Stavudine | 2 | 2008 | 8 | 0.350 |
Why?
| | Dideoxynucleosides | 2 | 2008 | 21 | 0.350 |
Why?
| | Health Promotion | 3 | 2022 | 741 | 0.350 |
Why?
| | Humans | 50 | 2022 | 137585 | 0.340 |
Why?
| | Adult | 31 | 2020 | 37929 | 0.340 |
Why?
| | Lamivudine | 2 | 2008 | 63 | 0.340 |
Why?
| | Social Support | 1 | 2014 | 618 | 0.320 |
Why?
| | Subcutaneous Fat | 3 | 2010 | 81 | 0.310 |
Why?
| | Male | 28 | 2020 | 67762 | 0.310 |
Why?
| | Vaccines | 1 | 2014 | 406 | 0.300 |
Why?
| | Anti-Retroviral Agents | 4 | 2013 | 233 | 0.300 |
Why?
| | Public Health | 1 | 2013 | 588 | 0.290 |
Why?
| | Zidovudine | 1 | 2008 | 78 | 0.280 |
Why?
| | Vaccination | 3 | 2013 | 1381 | 0.280 |
Why?
| | Insurance, Health | 3 | 2015 | 283 | 0.270 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 213 | 0.260 |
Why?
| | HIV Protease Inhibitors | 1 | 2007 | 69 | 0.260 |
Why?
| | Health Status | 1 | 2011 | 792 | 0.250 |
Why?
| | Papillomavirus Vaccines | 3 | 2013 | 238 | 0.240 |
Why?
| | Patient Compliance | 1 | 2009 | 581 | 0.240 |
Why?
| | Primary Health Care | 2 | 2014 | 1738 | 0.230 |
Why?
| | Middle Aged | 20 | 2019 | 33479 | 0.230 |
Why?
| | Indians, North American | 1 | 2011 | 643 | 0.230 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2010 | 271 | 0.230 |
Why?
| | Risk Assessment | 3 | 2013 | 3457 | 0.220 |
Why?
| | Attitude of Health Personnel | 1 | 2012 | 1171 | 0.220 |
Why?
| | Community-Institutional Relations | 2 | 2015 | 98 | 0.220 |
Why?
| | Physicians | 1 | 2012 | 910 | 0.210 |
Why?
| | Diagnostic Errors | 1 | 2005 | 170 | 0.210 |
Why?
| | HIV-1 | 4 | 2011 | 864 | 0.200 |
Why?
| | Program Evaluation | 3 | 2016 | 898 | 0.200 |
Why?
| | Follow-Up Studies | 6 | 2017 | 5131 | 0.190 |
Why?
| | Pelvic Inflammatory Disease | 1 | 2022 | 11 | 0.190 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1329 | 0.190 |
Why?
| | Intrauterine Devices | 1 | 2022 | 31 | 0.190 |
Why?
| | Reproductive Health | 1 | 2022 | 90 | 0.180 |
Why?
| | Long-Acting Reversible Contraception | 1 | 2022 | 33 | 0.180 |
Why?
| | United States | 9 | 2020 | 14841 | 0.180 |
Why?
| | Focus Groups | 2 | 2014 | 522 | 0.180 |
Why?
| | Human papillomavirus 16 | 2 | 2011 | 35 | 0.180 |
Why?
| | Electronic Health Records | 2 | 2022 | 1069 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 3 | 2014 | 806 | 0.170 |
Why?
| | Allied Health Personnel | 1 | 2020 | 46 | 0.160 |
Why?
| | Heroin | 1 | 2020 | 31 | 0.160 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2111 | 0.150 |
Why?
| | Incidence | 4 | 2013 | 2804 | 0.150 |
Why?
| | Prevalence | 5 | 2013 | 2734 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2020 | 245 | 0.150 |
Why?
| | Multivariate Analysis | 4 | 2009 | 1509 | 0.140 |
Why?
| | Lipids | 3 | 2009 | 672 | 0.140 |
Why?
| | Inpatients | 1 | 2022 | 500 | 0.140 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 2 | 2010 | 11 | 0.140 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2013 | 257 | 0.140 |
Why?
| | Cost-Benefit Analysis | 2 | 2013 | 591 | 0.130 |
Why?
| | Adipose Tissue | 4 | 2010 | 635 | 0.130 |
Why?
| | Child | 5 | 2019 | 21935 | 0.130 |
Why?
| | Medicaid | 1 | 2020 | 435 | 0.130 |
Why?
| | Reminder Systems | 1 | 2017 | 169 | 0.120 |
Why?
| | Young Adult | 5 | 2019 | 13209 | 0.120 |
Why?
| | Organizational Case Studies | 1 | 2015 | 78 | 0.120 |
Why?
| | Drug Overdose | 1 | 2020 | 347 | 0.120 |
Why?
| | Women's Health | 2 | 2009 | 372 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 493 | 0.110 |
Why?
| | Direct Service Costs | 1 | 2014 | 9 | 0.110 |
Why?
| | Health Plan Implementation | 1 | 2015 | 142 | 0.110 |
Why?
| | Immunization Schedule | 1 | 2015 | 197 | 0.110 |
Why?
| | Cervix Uteri | 2 | 2011 | 48 | 0.110 |
Why?
| | National Health Programs | 1 | 2013 | 23 | 0.100 |
Why?
| | AIDS Dementia Complex | 1 | 2013 | 51 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2020 | 552 | 0.100 |
Why?
| | Sex Counseling | 2 | 2003 | 4 | 0.100 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5472 | 0.100 |
Why?
| | Models, Immunological | 1 | 2013 | 100 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1050 | 0.100 |
Why?
| | Mass Screening | 2 | 2013 | 1287 | 0.100 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 273 | 0.100 |
Why?
| | Time Factors | 4 | 2013 | 6828 | 0.090 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2011 | 42 | 0.090 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2011 | 36 | 0.090 |
Why?
| | Human papillomavirus 18 | 1 | 2011 | 16 | 0.090 |
Why?
| | Schools | 1 | 2014 | 461 | 0.080 |
Why?
| | Hospitalization | 1 | 2020 | 2199 | 0.080 |
Why?
| | Contraceptive Agents, Female | 1 | 2011 | 80 | 0.080 |
Why?
| | Self Efficacy | 1 | 2014 | 396 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 107 | 0.080 |
Why?
| | Urban Population | 2 | 2004 | 479 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 530 | 0.080 |
Why?
| | Long QT Syndrome | 1 | 2011 | 70 | 0.080 |
Why?
| | Health Education | 1 | 2013 | 341 | 0.080 |
Why?
| | Regression Analysis | 2 | 2009 | 1024 | 0.080 |
Why?
| | Learning | 1 | 2013 | 409 | 0.080 |
Why?
| | Risk-Taking | 2 | 2002 | 348 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2013 | 546 | 0.080 |
Why?
| | Life Style | 1 | 2011 | 490 | 0.080 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1023 | 0.070 |
Why?
| | Pilot Projects | 1 | 2014 | 1710 | 0.070 |
Why?
| | Virology | 1 | 2008 | 24 | 0.070 |
Why?
| | Cohort Studies | 4 | 2008 | 5742 | 0.070 |
Why?
| | Odds Ratio | 1 | 2009 | 1070 | 0.060 |
Why?
| | Aged | 6 | 2011 | 23961 | 0.060 |
Why?
| | Osteoporosis | 1 | 2009 | 243 | 0.060 |
Why?
| | Risk Factors | 5 | 2011 | 10388 | 0.060 |
Why?
| | Bone Density | 1 | 2009 | 489 | 0.060 |
Why?
| | Didanosine | 1 | 2005 | 13 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1587 | 0.060 |
Why?
| | Genital Diseases, Female | 1 | 2005 | 28 | 0.060 |
Why?
| | Prospective Studies | 2 | 2009 | 7604 | 0.060 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1289 | 0.060 |
Why?
| | Vaginosis, Bacterial | 1 | 2004 | 12 | 0.060 |
Why?
| | Urban Health Services | 1 | 2004 | 63 | 0.060 |
Why?
| | Abortion, Therapeutic | 1 | 2003 | 3 | 0.050 |
Why?
| | Spermatocidal Agents | 1 | 2003 | 7 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 3 | 2010 | 269 | 0.050 |
Why?
| | Pregnancy Rate | 1 | 2003 | 65 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1477 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2003 | 91 | 0.050 |
Why?
| | Hysterectomy | 1 | 2003 | 129 | 0.050 |
Why?
| | Community Health Centers | 1 | 2002 | 60 | 0.050 |
Why?
| | Program Development | 2 | 2015 | 364 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2009 | 2844 | 0.050 |
Why?
| | Postoperative Care | 1 | 2003 | 261 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.040 |
Why?
| | Risk | 1 | 2004 | 912 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2186 | 0.040 |
Why?
| | Forecasting | 1 | 2002 | 389 | 0.040 |
Why?
| | Insulin Resistance | 2 | 2009 | 1208 | 0.040 |
Why?
| | Papillomaviridae | 2 | 2013 | 125 | 0.040 |
Why?
| | Counseling | 1 | 2003 | 391 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1946 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2004 | 394 | 0.040 |
Why?
| | Child, Preschool | 1 | 2014 | 11074 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2002 | 1266 | 0.040 |
Why?
| | Absorptiometry, Photon | 2 | 2010 | 259 | 0.040 |
Why?
| | Logistic Models | 1 | 2004 | 2074 | 0.040 |
Why?
| | Insulin | 2 | 2009 | 2409 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2003 | 786 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2022 | 15657 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2031 | 0.030 |
Why?
| | Viral Load | 2 | 2011 | 466 | 0.030 |
Why?
| | Electric Impedance | 2 | 2007 | 107 | 0.030 |
Why?
| | Automation | 1 | 2015 | 95 | 0.030 |
Why?
| | Motivation | 1 | 2020 | 570 | 0.030 |
Why?
| | Cell Phone | 1 | 2015 | 76 | 0.030 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 15 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2013 | 60 | 0.020 |
Why?
| | Data Collection | 1 | 2015 | 673 | 0.020 |
Why?
| | Coitus | 1 | 2011 | 22 | 0.020 |
Why?
| | Sentinel Surveillance | 1 | 2011 | 49 | 0.020 |
Why?
| | Sex Factors | 2 | 2008 | 2071 | 0.020 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2011 | 63 | 0.020 |
Why?
| | Needs Assessment | 1 | 2013 | 376 | 0.020 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2010 | 14 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 118 | 0.020 |
Why?
| | Sexual Partners | 1 | 2011 | 186 | 0.020 |
Why?
| | Health Behavior | 1 | 2015 | 762 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 171 | 0.020 |
Why?
| | Adolescent Behavior | 1 | 2013 | 530 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 246 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2009 | 786 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2008 | 137 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2057 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 209 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1062 | 0.010 |
Why?
| | Anthropometry | 1 | 2005 | 213 | 0.010 |
Why?
| | Liver Diseases | 1 | 2008 | 315 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2011 | 10811 | 0.010 |
Why?
| | Prognosis | 1 | 2013 | 4030 | 0.010 |
Why?
| | Metronidazole | 1 | 2004 | 20 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2009 | 380 | 0.010 |
Why?
| | Verbal Behavior | 1 | 2004 | 40 | 0.010 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2004 | 184 | 0.010 |
Why?
| | Device Removal | 1 | 2003 | 136 | 0.010 |
Why?
| | RNA, Viral | 1 | 2005 | 656 | 0.010 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 255 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1060 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5778 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2004 | 740 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3295 | 0.010 |
Why?
| | Smoking | 1 | 2007 | 1627 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2691 | 0.010 |
Why?
| | Body Mass Index | 1 | 2007 | 2389 | 0.010 |
Why?
| | Pain | 1 | 2003 | 756 | 0.010 |
Why?
|
|
Shlay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|